Co-Diagnostics, Inc.
CODXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCo-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in. With a market capitalization of $8.1M, it sits in micro-cap territory. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
Market Cap
$8.1M
Beta
2.85
P/E (TTM)
—
P/E (Fwd)
-1.40
EPS (TTM)
$-25.89
EPS (Fwd)
$-0.83
ROE
-174.8%
ROA
-59.6%
Cash
$3.6M
Total Debt
$1.8M
Free CF
-$17.5M
52W Change
-87.5%
Annual Financials
Cash vs Debt
Where CODX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CODX finished 53.60% below its 150-day moving average ($2.50) and 68.90% below its 200-day moving average ($3.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CODX overbought or oversold?
At the September 3, 2026 close, CODX's RSI(14) was 26.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Co-Diagnostics, Inc. holds $3.6M in cash against $1.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$17.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -174.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $97.9M (2021) to $622K (2025), a 99% decline worth watching.
A beta of 2.85 means CODX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CODX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CODX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.